Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Population
Go back to Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Population| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 239.56 -5.95 (2.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $245.51 | 52 Week High | $109.10 | |||
| Open | $246.41 | 52 Week Low | $31.38 | |||
| Day High | $246.49 | P/E | N/A | |||
| Day Low | $238.51 | EPS | $-1.45 | |||
| Volume | 2,756,179 | |||||
